Two UK Deaths Feared Linked to Weight-Loss Jabs Prompt MHRA Safety Review
Two deaths in Northern Ireland, involving a man and a woman aged in their 40s and 60s, have been reported to the UK's drug watchdog due to suspected links with popular weight-loss medications. These fatalities are part of over 500 adverse drug reaction reports submitted from Northern Ireland between 2024 and 2025, which are suspected to be associated with GLP-1 medications such as Mounjaro and an unspecified semaglutide.
MHRA Clarifies Reports and Emphasises Safety Monitoring
The Medicine and Healthcare Regulatory Agency (MHRA) has clarified that these reports indicate suspicion rather than confirmed causation. However, the agency stressed that its robust safety monitoring systems remain actively in place to assess potential risks. Among the reports, 242 were classified as "serious", including one case involving a child under the age of 10. Healthcare professionals submitted 419 of these reports, while patients or carers made 92 submissions.
Benefits vs. Risks: Official Statement from MHRA
Dr. Alison Cave, the MHRA's chief safety officer, stated that the benefits of GLP-1 medicines currently outweigh potential risks when used as licensed. She urged continued vigilance and reporting through the Yellow Card scheme to ensure ongoing safety evaluations. This call to action underscores the importance of monitoring adverse effects in real-time to protect public health.
Context and Related Concerns
This news follows warnings from public figures, such as EastEnders star Nina Wadia, about the potential dangers of weight-loss jabs. The reports highlight growing concerns over the safety of these widely used medications, prompting further investigation by regulatory bodies. The MHRA's response aims to balance the therapeutic advantages of GLP-1 drugs with necessary caution, ensuring that patients and healthcare providers remain informed and proactive in reporting any issues.
